What are the causes of mild pulmonary hypertension?

Causes of Mild Pulmonary Hypertension

Mild pulmonary hypertension is most commonly caused by left heart disease (particularly diastolic dysfunction and valvular disease), followed by chronic lung diseases (COPD, interstitial lung disease), with the vast majority of cases related to cardiopulmonary and metabolic comorbidities rather than primary pulmonary vascular disease.

Primary Classification Framework

The causes of mild PH follow the established ESC/ERS clinical classification system 1:

Group 1: Pulmonary Arterial Hypertension (Rare in Mild PH)

• Idiopathic PAH - uncommon presentation as mild disease
• Heritable PAH - BMPR2 and other genetic mutations
• Drug and toxin-induced - appetite suppressants, dasatinib, methamphetamines
• Associated conditions:
  • Connective tissue diseases (systemic sclerosis, lupus, mixed connective tissue disease)
  • HIV infection
  • Portal hypertension
  • Congenital heart disease
  • Schistosomiasis

Group 2: Left Heart Disease (Most Common Cause)

This is the predominant cause of mild PH, accounting for the majority of cases 2, 1:

• Left ventricular systolic dysfunction - up to 60% of severe LV dysfunction patients develop PH
• Left ventricular diastolic dysfunction - the leading mechanism in mild PH, particularly with:
  • Obesity
  • Metabolic syndrome
  • Aging-related increased PA stiffness
• Valvular disease:
  • Mitral valve disease (virtually 100% with severe symptomatic disease)
  • Aortic stenosis (up to 65% with symptomatic disease)
• Congenital/acquired left heart inflow/outflow obstruction

Group 3: Lung Diseases and/or Hypoxia (Common)

• COPD - mild-to-moderate PH is common 3, 4
• Interstitial lung disease - develops with advanced disease 5
• Sleep-disordered breathing
• Alveolar hypoventilation disorders
• Chronic high altitude exposure
• Mixed restrictive/obstructive patterns

Group 4: Chronic Thromboembolic Disease (Rare)

• Chronic thromboembolic pulmonary hypertension (CTEPH)
• Pulmonary artery obstructions (tumors, arteritis, congenital stenoses)

Group 5: Unclear/Multifactorial Mechanisms

• Hematological disorders - chronic hemolytic anemia, myeloproliferative disorders, post-splenectomy
• Systemic disorders - sarcoidosis, histiocytosis, lymphangioleiomyomatosis
• Metabolic disorders - glycogen storage disease, Gaucher disease, thyroid disorders
• Chronic renal failure (with or without dialysis)

Pathophysiological Mechanisms in Mild PH

The 2021 Lancet analysis provides critical insight into mild PH pathophysiology 2:

Primary Mechanisms:

1. Increased left atrial pressure - approximately 22% of patients with mPAP 19-24 mmHg have elevated pulmonary capillary wedge pressure >15 mmHg, rising to 78% when mPAP >25 mmHg
2. Increased pulmonary artery stiffness - age-related vascular changes
3. Pulmonary vascular remodeling - impaired vasoreactivity in the setting of comorbidities
4. High stroke volume index - recent data shows this is an independent predictor in mild precapillary PH 6, 7
5. Backward transmission from borderline PAWP - in unclassified PH 6

Contributing Factors:

• Age - PASP increases with age (correlation r=0.19-0.48), though elevated PASP remains associated with poor outcomes independent of age 2
• Obesity and metabolic disorders - independently associated with elevated ePASP
• Cardiopulmonary comorbidities - often multiple conditions coexist
• Cigarette smoke - may cause initial endothelial injury even before overt lung disease develops 4

Clinical Phenotypes of Mild PH

Recent phenotyping studies reveal important patterns 6, 7:

• 76% have left heart or lung disease as the underlying cause
• Unclassified PH (mPAP 21-24 mmHg with PVR ≤2 WU) is mainly related to:
  • Pulmonary overflow from high cardiac output
  • Backward transmission from borderline elevated PAWP
• Mild precapillary PH (mPAP 21-24 mmHg with PVR >2 WU):
  • Typically associated with comorbidities
  • NOT necessarily an early stage of PAH
  • Stroke volume index is the key prognostic marker
  • Only a limited number with PAH risk factors progress to overt PAH

Critical Clinical Pitfalls

1. Do not assume mild PH is benign - even mildly elevated PASP (30-50 mmHg) is associated with poor outcomes independent of age and comorbidities 2

2. Recognize that mild PH acts as both:

   • A risk marker on its own
   • A risk modifier in the presence of comorbidities

3. Avoid missing "out-of-proportion" PH - a small subset of COPD patients present with mPAP >35-40 mmHg with relatively preserved lung function that cannot explain prominent symptoms 3

4. Careful phenotyping is essential - only a small subset may benefit from PAH-specific therapies; most require treatment of underlying comorbidities 6

5. Transitory increases occur - PH may worsen during exacerbations, exercise, and sleep even when resting pressures are only mildly elevated 3, 4